Omisirge is the world’s 1st U.S. FDA approved product that is a expanded umbilical cord blood cell therapy.

It is also the only allogeneic stem cell therapy approved by the U.S. FDA on the basis of a global randomized Phase 3 trial.

Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress.